Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2005-08-02
2005-08-02
Jones, Dameron L. (Department: 1616)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C424S001110, C424S001650, C536S063000
Reexamination Certificate
active
06923950
ABSTRACT:
System and method for radiographic imaging of tissue using a non-radioactive, radio-opaque imaging agent that accumulates intracellularly in tissue in proportion to its functional, or physiological, activity. In one embodiment, the imaging agent is a cell-membrane permeable, radio-opaque, high affinity ligand for the intracellular enzyme hexokinase. The imaging agent is administered to a patient, and after an accumulation interval, radiographic images are acquired. The imaging agent preferentially accumulates in malignant tissue and increases its radio-opacity because of its elevated glucose metabolic rate relative to benign and normal tissue. The tissue being examined is transilluminated by X-ray beams with preselected different mean energy spectra, and a separate radiographic image is acquired during transillumination by each beam. An image processing system performs a weighted combination of the acquired images to produce a single displayed image. The image processing procedure isolates the radiographic density contributed solely by differential accumulation of the imaging agent in malignant, benign, and normal tissue. The system and method thus provides a functional image displayed with the anatomical detail and spatial resolution of a radiographic image. The viewer may interactively control the relative proportion of radiographic density contributed by imaging agent, soft tissue, and bone to the displayed image, allowing the display of functional and anatomical information in complete registration, and facilitating localization of malignant tissue in relation to nearby anatomical structures. In other embodiments, the system and method may be used to detect enzymes, nucleic acids, coenzymes, fatty acids, and other cellular targets in diagnostic imaging applications.
REFERENCES:
patent: 2840602 (1958-06-01), Larsen
patent: 3701771 (1972-10-01), Almen et al.
patent: 3702866 (1972-11-01), Salvesen et al.
patent: 3854049 (1974-12-01), Mistretta et al.
patent: 3974386 (1976-08-01), Mistretta et al.
patent: 4021481 (1977-05-01), Almen et al.
patent: 4139605 (1979-02-01), Felder et al.
patent: 4160015 (1979-07-01), Wiegert
patent: 4243653 (1981-01-01), Sovak et al.
patent: 4250113 (1981-02-01), Nordal et al.
patent: 4341756 (1982-07-01), Sovak et al.
patent: 4348377 (1982-09-01), Felder et al.
patent: 4352788 (1982-10-01), Felder et al.
patent: 4364921 (1982-12-01), Speck et al.
patent: 4406878 (1983-09-01), DeBoer
patent: 4439613 (1984-03-01), Sovak et al.
patent: 4455292 (1984-06-01), Bertoni
patent: 4474747 (1984-10-01), Dimo et al.
patent: 4716225 (1987-12-01), Ledley et al.
patent: 4766110 (1988-08-01), Ryan et al.
patent: 4887604 (1989-12-01), Shefer et al.
patent: 5043152 (1991-08-01), Schaefer et al.
patent: 5093042 (1992-03-01), Counsell et al.
patent: 5141739 (1992-08-01), Jung et al.
patent: 5198977 (1993-03-01), Salb
patent: 5408996 (1995-04-01), Salb
patent: 5466786 (1995-11-01), Buhr et al.
patent: 5525327 (1996-06-01), Baker et al.
patent: 5609851 (1997-03-01), Bennani et al.
patent: 5610289 (1997-03-01), Cook et al.
patent: 5650135 (1997-07-01), Contag et al.
patent: 5728527 (1998-03-01), Singer et al.
patent: 5729620 (1998-03-01), Wang
patent: 5763208 (1998-06-01), Bischofberger et al.
patent: 5796862 (1998-08-01), Pawlicki et al.
patent: 5817289 (1998-10-01), Klaveness et al.
patent: 6071491 (2000-06-01), Epstein et al.
patent: 6226352 (2001-05-01), Salb
patent: 2001/0031035 (2001-10-01), Salb et al.
patent: 2001/0038682 (2001-11-01), Salb
patent: 0 270 340 (1988-06-01), None
patent: WO 98/57669 (1998-12-01), None
patent: WO 01/67958 (2001-09-01), None
Agrawal S. et al., “Pharmacokinetics of oligonucleotides”,Ciba Foundation Symposium 209, pp. 60-78 (1997).
Aleshin A.E. et al., “The mechanism of regulation of hexokinase: new insights from the crystal structure of recombinant human brain hexokinase complexed with glucose and glucose-6-phosphate”,Structure6(1):39-50 (1998).
Alier C.B. et al., “Flow cytometric analysis of glucose transport by rat brain cells”,Cytometry27:262-268 (1997).
Alpert N.M. et al., “Improved methods for image registration”,Neuroimage3:10-18 (1996).
Arora K.K. et al., “Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by lntramitochondrialIy generated ATP”,J. Biol. Chem.263(33):17422-17428 (Nov. 25, 1998).
Barnett J.E.G. et al., “Structural requirements for binding to the sugar-transport system of the human erythrocyte”,Biochem. J.131:211-221 (1973).
Barnett J.E.G. et al., “Evidence for two asymmetric conformational states in the human erythorocyte sugar-trasport system”,Biochem. J.145:417-429 (1975).
Binder C. et al., “Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues”,Anticancer Research, 17:4299-4304 (1997).
Bird R.E. et al., “Analysis of cancers missed at screening mammography”,Radiology184:613-617 (1992).
Chien K.R. et al. “In vivo esterification of a synthetic 1251-labeled fatty acid into cardiac glycerolipids”,Am. J. Physiol.245:H693-H697 (1983).
Coats E.A. et al., “Exploring the hexokinase glucose binding site through correlation analysis and molecular modeling of glucosamine inhibitors”,J. Enz. Inhib.6:271-282 (1993).
Colville C.A. et al., “Analysis of the structural requirements of sugar binding to the liver, brain and insulin-responsive glucose transporters expressed in oocytes,”Biochem. J.294:753-760 (1993).
Conti P.S. et al., “PET and [18F]-FDG in oncolgoy: a clinical update”,Nuc. Med.&Biol.23:717-735 (1996).
Crooke S. et al. (eds).: “Designer Antisense Oligonucleotides: conjugation chemistry and functionality placement,”Antisense Research and Applications, Ch. 17, pp. 303-349, CRC Press, Boca Raton (1993).
Dewanjee M.K. et al., “Noninvasive imaging of c-myconcogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model”,J. Nuc. Med.35(6):1054-1063 (1994).
Eisenhut M. et al., “Trapping and metabolism of radioiodinated PHIPA 3-10 in the rat myocardium”,J. Nucl. Med.38(12):1864-1869 (1997).
Ekholm S.E. et al., “Neural tissue uptake and clearance of iohexol following lumbar myelography in rabbits”,Acta Radiologica Diagnosis(Stockh). 26:331-336 (1985).
Elmore J.G. et al., “Ten-year risk of false positive screening mammograms and clinical breast examinations”,N. Eng. J. Med.338(16):1089-1096 (1998).
Friston K.J. et al., “Spatial registration and normalization of images”,Human Brain Mapping2:165-189 (1995).
Ghose A.K. et al., “Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships III: Modeling hydrophobic interactions”,J. Comp. Chem.9(1):80-90 (1988).
Gjedde A.: “The blood-brain barrier is impermeable to metrizamide”,Acta Neurol. Scandinav.66:392-395 (1982).
Golman K.: “Distribution and retention of 1251-labeled metrizamide after intravenous and suboccipital injection in rabbit, rat, and cat”,Acta Radiol. Suppl.S335:300-311 (1973).
Hansch C. et al., “Linear relationships between lipophilic character and biological activity of drugs”,J. Pharm. Sci.61(1):1-19 (Jan. 1972).
Hansch C. et al., “Exploring QSAR: fundamentals and applications in chemistry and biology”, pp. 97-168,Amer. Chem. Soc., Washington, DC (1995).
Henry C. et al., “[1231]-6deoxy-6-iodo-D-glucose (6DIG).: a potential tracer of glucose transport”,Nuc. Med. Biol.24:527-534 (1997).
Hoh C.K. et al., “PET in oncology: will it replace the other modalities?”,Seminars in Nuc. Med.27(2)94-106 (Apr. 1997).
Hosokawa R., et al., “Myocardial kinetics of Iodine-123-BMIPP in canine myocardium after regional ischemia and reperfusion: implications for clinical SPECT”,J. Nuc
Blakely , Sokoloff, Taylor & Zafman LLP
Jones Dameron L.
Veritas Pharmaceuticals, Inc.
LandOfFree
System and method for radiographic imaging of tissue does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with System and method for radiographic imaging of tissue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and System and method for radiographic imaging of tissue will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3503040